ConductScience.org, home
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
API referenceFor AI assistants

Paper · 28416604

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

1 to 20 of 32

Download this page as JSON
PMIDTitleJournalYearIn PapersSource
42,124,891Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression.Bladder Cancer2026https://conductscience.org/library/papers/42124891PubMed
41,804,750Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.Clin Transl Med2026https://conductscience.org/library/papers/41804750PubMed
41,487,403Molecular mechanisms of human papillomavirus-induced tongue carcinogenesis: A systematic review.J Oral Biol Craniofac Res2026https://conductscience.org/library/papers/41487403PubMed
41,125,751Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling.Sci Rep2025https://conductscience.org/library/papers/41125751PubMed
40,001,320A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment.Thorac Cancer2025https://conductscience.org/library/papers/40001320PubMed
39,001,460Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.Cancers (Basel)2024https://conductscience.org/library/papers/39001460PubMed
38,710,951Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Nat Med2024https://conductscience.org/library/papers/38710951PubMed
37,980,453Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.Sci Rep2023https://conductscience.org/library/papers/37980453PubMed
37,889,382
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial.
Invest New Drugs2023https://conductscience.org/library/papers/37889382PubMed
36,551,764Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.Biomedicines2022https://conductscience.org/library/papers/36551764PubMed
36,209,184Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.J Hematol Oncol2022https://conductscience.org/library/papers/36209184PubMed
36,179,047FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.Proc Natl Acad Sci U S A2022https://conductscience.org/library/papers/36179047PubMed
35,582,716Overcome cancer drug resistance by targeting epigenetic modifications of centrosome.Cancer Drug Resist2019https://conductscience.org/library/papers/35582716PubMed
35,582,593Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy.Cancer Drug Resist2019https://conductscience.org/library/papers/35582593PubMed
35,501,832Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.BMC Cancer2022https://conductscience.org/library/papers/35501832PubMed
35,384,983Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.Einstein (Sao Paulo)2022https://conductscience.org/library/papers/35384983PubMed
35,138,907A functional genomic approach to actionable gene fusions for precision oncology.Sci Adv2022https://conductscience.org/library/papers/35138907PubMed
34,638,374Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.Cancers (Basel)2021https://conductscience.org/library/papers/34638374PubMed
34,207,779Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling.Cells2021https://conductscience.org/library/papers/34207779PubMed
34,098,465Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.Eur J Med Chem2021https://conductscience.org/library/papers/34098465PubMed

papers-2026-11-12-0.1.0

Next page

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/28416604/cited_by

API referenceFor AI assistants